Along with the comprehensive molecular profiling of cancer-related genes, the insight into cancer treatment has been revolutionized and targeting the epidermal growth factor receptor (EGFR) through the tyrosine kinase inhibitor (TKI) has been regarded as an effective therapeutic strategy for NSCLC from a clinical oncology perspective [3,4]. This evidence concerns the gene EGFR and cancer.